News
Tofacitinib Slows Joint Damage in Rheumatoid Arthritis
Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept